These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 34435168)
61. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024 [TBL] [Abstract][Full Text] [Related]
62. Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature. Abdel-Rahman O; Fouad M Crit Rev Oncol Hematol; 2015 May; 94(2):238-50. PubMed ID: 25638704 [TBL] [Abstract][Full Text] [Related]
63. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma. Tegos T; Tegos K; Dimitriadou A; Dimitriadis G J BUON; 2019; 24(4):1340-1353. PubMed ID: 31646776 [TBL] [Abstract][Full Text] [Related]
64. Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. Manneh R; Lema M; Carril-Ajuria L; Ibatá L; Martínez S; Castellano D; de Velasco G Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327380 [TBL] [Abstract][Full Text] [Related]
66. Radical versus partial nephrectomy for T1 non-clear cell renal cell carcinoma. Hu X; Wang Y; Shao Y; Wu K; Tang Y; Ren S; Li X Eur J Surg Oncol; 2023 Aug; 49(8):1519-1523. PubMed ID: 36958950 [TBL] [Abstract][Full Text] [Related]
67. Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma. An J; Packiam VT; Chennamadhavuni A; Richards J; Jain J; Mott SL; Garje R Front Oncol; 2021; 11():786307. PubMed ID: 35083144 [TBL] [Abstract][Full Text] [Related]
68. Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022. Maughan BL Curr Oncol Rep; 2022 Sep; 24(9):1201-1208. PubMed ID: 35438388 [TBL] [Abstract][Full Text] [Related]
69. Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials. Wei C; Wang S; Ye Z; Chen Z Int Braz J Urol; 2018; 44(2):219-237. PubMed ID: 29211397 [TBL] [Abstract][Full Text] [Related]
76. The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature. Ventriglia J; Passarelli A; Pisano C; Cecere SC; Rossetti S; Feroce F; Forte M; Casartelli C; Tambaro R; Pignata S; Perversi F; Di Napoli M Crit Rev Oncol Hematol; 2023 Aug; 188():104036. PubMed ID: 37263397 [TBL] [Abstract][Full Text] [Related]
77. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. Pal SK; McGregor B; Suárez C; Tsao CK; Kelly W; Vaishampayan U; Pagliaro L; Maughan BL; Loriot Y; Castellano D; Srinivas S; McKay RR; Dreicer R; Hutson T; Dubey S; Werneke S; Panneerselvam A; Curran D; Scheffold C; Choueiri TK; Agarwal N J Clin Oncol; 2021 Nov; 39(33):3725-3736. PubMed ID: 34491815 [TBL] [Abstract][Full Text] [Related]
78. Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma. Haaland B; Chopra A; Acharyya S; Fay AP; Lopes Gde L BMC Cancer; 2014 Aug; 14():592. PubMed ID: 25127891 [TBL] [Abstract][Full Text] [Related]
79. Genomic profiles of renal cell carcinoma in a small Chinese cohort. Tai S; Xu DD; Yu Z; Guan Y; Yin S; Xiao J; Xue S; Liang C Front Oncol; 2023; 13():1095775. PubMed ID: 37427096 [TBL] [Abstract][Full Text] [Related]